Acceptable Liver Transplant Outcomes Seen After ICI Therapy for Liver Cancer
By Elana Gotkine HealthDay Reporter
FRIDAY, Aug. 16, 2024 -- For patients with hepatocellular carcinoma (HCC), immune checkpoint inhibitor (ICI) use prior to liver transplant (LT) does not worsen outcomes, according to research published online July 10 in the Journal of Hepatology.
Mohammad Saeid Rezaee-Zavareh, from the Middle East Liver Diseases Center in Tehran, Iran, and colleagues summarized the impact of ICI use on post-LT outcomes in an individual patient data meta-analysis. Data were included for 91 eligible patients.
The researchers found that during a median follow-up of 690.0 days, there were 24, nine, and nine allograft rejections, HCC recurrences, and deaths, respectively. Associations with allograft rejection were seen for age (adjusted hazard ratio [aHR] per 10 years, 0.72) and ICI washout time (aHR per one week, 0.92). For patients with ≤20 percent probability of allograft rejection, the median washout period was 94 days. There was no difference in overall survival seen between cases with and without allograft rejection. Fewer median ICI cycles were seen for individuals with versus without HCC recurrence (4.0 versus 8.0). A lower proportion of patients were within Milan criteria post-ICI among those with versus without recurrence (16.7 versus 65.3 percent).
"We concluded that with a 90-day gap between the last dose of immunotherapy and liver transplant, the risk of organ rejection is no greater than if the patient had never received immunotherapy," senior author Ju Dong Yang, M.D., from Cedars-Sinai Medical Center in Los Angeles, said in a statement.
Several authors disclosed ties to the biopharmaceutical and medical device industries.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Standard-Criteria Kidney Transplant Offers Clear Survival Benefit Over Continued Dialysis
TUESDAY, June 10, 2025 -- Transplantation with standard-criteria kidney offers a clear survival benefit, but this decreases with age and for those with a history of cardiovascular...
Early, Preemptive Kidney Transplant No Aid to Mortality
FRIDAY, June 6, 2025 -- There is no mortality benefit to receive an early, preemptive kidney transplant, according to a study published in the May issue of Transplantation...
Post-Kidney Transplant Adverse Outcomes Increased With BMI-BSA Obesity
TUESDAY, May 27, 2025 -- Combined body mass index (BMI)-body surface area (BSA) obesity is associated with an increased risk for post-kidney transplant (KT) adverse outcomes...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.